Tests izalontamab brengitecan versus chemotherapy in lung cancer after EGFR drug failure
Compares izalontamab brengitecan with chemotherapy in adults with EGFR-mutated lung cancer that worsened.
Plain-language title generated from the registry record
Registry title: IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Key facts
- Where
- Barcelona, Madrid, Majadahonda, Málaga, Sevilla, Valencia, and Zaragoza, SpainSee the 10 sites
- Phase
- Phase 2/3
Where in Spain
- Hospital de la Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario La PazMadrid, SpainNot yet recruiting
- Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainNot yet recruiting
- Hospital Universitario Regional de MálagaMálaga, SpainNot yet recruiting
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainNot yet recruiting
- Hospital Universitario Y Politecnico La FeValencia, SpainNot yet recruiting
- Hospital Clinico Universitario Lozano BlesaZaragoza, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb Services Unlimited Company
- Trial code
- EU 2025-521908-22-00
- Record updated
- 13 October 2026
- Original description
Phase 3: To compare the progression-free survival of iza-bren at RP3D vs platinum-based chemotherapy in participants with advanced EGFRmt NSCLC cancer and disease progression after any 3rd generation TKIsRead full original descriptionShow less
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
Phase 3: To compare the progression-free survival of iza-bren at RP3D vs platinum-based chemotherapy in participants with advanced EGFRmt NSCLC cancer and disease progression after any 3rd generation TKIs
Inclusion: Non-squamous NSCLC, not amenable to treatment in curative intent; Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation); Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting; Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).
Exclusion: Poorly controlled systemic medical conditions; Inadequate organ function and/or bone marrow reserve; Leptomeningeal metastases or spinal cord compression.